Friday, 16 Nov 2018

You are here

Nurse Led Gout Management Highly Effective

UK researchers have shown that nurse-led gout management, using a treat-to-target urate-lowering strategy, is efficacious and cost-effective compared with usual physicain care. The results are published in the recent Lancet edition.

Worldwide, gout management is suboptimal. In the UK only 40% of gout patients receive urate-lowering therapy, and fewer ever achieve a target serum urate (< 6mg/d) concentration.

Gout patients with a gout flare in the last 12 months were randomly assigned to receive either specially trained, nurse-led care or continue with GP-led usual care. The primary endpoint was the percentage of participants who achieved serum urate concentrations less than 360 μmol/L (6 mg/dL) at 2 years.

A total of 517 gout patients were enrolled, of whom 255 were assigned nurse-led care and 262 usual care. The results were staggeringly in favor of nurse-led care, especially with regard to:

  • Uptake of and adherence to urate-lowering therapy (96% vs 56%, p = 0·0053 )
  • Achieving target urate at 2 years (95% vs 30%, RR 3·18, 95% CI 2·42–4·18, p<0·0001).
  • Fewer flares after 2 years (8% vs 24%;  p <0·0001)
  • The cost per QALY gained for the nurse-led intervention was £5066 at 2 years.

Community-based nurse-led care involving education and engagement of patients and a treat-to-target strategy for urate-lowering therapy achieved target serum urate concentrations and improved patient-centred outcomes in more than 90% of patients with gout.   This study underscores the benefits of educating and engaging patients in gout management and reaffirm the importance of a treat-to-target urate-lowering treatment strategy to improve patient-centred outcomes.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Treat-to-Target Strategy Cuts Mortality in Gout Patients

More intense treatment of gout with a treat-to-target strategy can reduce patients' risk for death, a Spanish researcher told a press conference Monday at the American College of Rheumatology annual meeting here.

TRIPLE Trial Results

Pegloticase has become an excellent option for management of patients with chronic refractory gout, although treatment may be limited by the development of anti-drug antibodies that lead to loss of serum urate (sUA) lowering effect.

Gout and the Social Determinants of Health

During a fascinating gout session on October 21, Hyon Choi presented an important paper (abstract 874) which used data from the Health Professionals Follow-up Study to try to understand the rapid increase in the incidence of gout in recent decades.

It's the Genes, Not the Diet that Raises Urate

Researchers from New Zealand find that in contrast with genetic contributions, diet explains very little variation in serum urate levels in the general population.

Allopurinol Shown to be Renal Protective

Neogi and colleagues have shown that standard doses of allopurinol (300 mg/day) were associated with a 13% lower risk of renal function deterioration in chronic gout patients - thus, allopurinol does not appear to impair renal function over time.